极早产儿早期低剂量氢化可的松治疗与2岁时神经发育结局的关联
该研究是对PREMILOC随机临床试验的探索性二次分析,纳入2008至2014年法国21个新生儿重症监护病房的极早产儿,比较出生后早期低剂量氢化可的松与安慰剂对2岁时神经发育的影响。结果显示,两组无神经发育障碍、轻度障碍及中重度障碍的分布无统计学显著差异(P=0.33),全局发育商均值也无统计学显著差异(91.7 vs 91.4,组间差值0.3,95%CI -2.7至3.4,P=0.83)。作者认为需进一步随机研究以明确氢化可的松对极早产儿神经发育的安全性。
要点
- 极早产儿早期低剂量氢化可的松与安慰剂相比,2岁时神经发育障碍分布无统计学显著差异(P=0.33)。
- 全局发育商均值氢化可的松组91.7 vs 安慰剂组91.4,组间差值0.3(95%CI -2.7至3.4,P=0.83)。
- 脑性瘫痪或其他主要神经损伤发生率两组间无显著差异。
核心结论
- 在极早产儿的探索性二次分析中,早期低剂量氢化可的松与2岁时神经发育无统计学显著差异相关。
- 作者认为需进一步随机研究以对氢化可的松在极早产儿中的神经发育安全性提供确切评估。
研究设计与样本
- PREMILOC随机临床试验的探索性二次分析,2008至2014年在法国21个新生儿重症监护病房开展,按胎龄组分层随机。
- 筛查1072例新生儿,523例随机分配至氢化可的松组(n=256)或安慰剂组(n=267),406例存活至2岁。
- 共379例(93%;女性46%)在2010至2016年完成神经发育评估,氢化可的松组194例、安慰剂组185例,中位校正年龄22个月(四分位距21-23个月)。
- 干预为出生后随机接受安慰剂或氢化可的松(0.5 mg/kg每日两次,共7天,随后0.5 mg/kg每日一次,共3天)。
主要发现
- 无神经发育障碍者氢化可的松组73% vs 安慰剂组70%,轻度障碍者20% vs 18%,中重度障碍者7% vs 11%,组间分布无统计学显著差异(P=0.33)。
- 全局发育商均值氢化可的松组91.7 vs 安慰剂组91.4,组间差值0.3(95%CI -2.7至3.4;P=0.83),无统计学显著差异。
- 脑性瘫痪或其他主要神经损伤的发生率两组间无显著差异。
关键数值与推荐
- 神经发育障碍依据标准化神经系统检查及修订版Brunet-Lézine量表评估,全局发育商量表常模均值100(标准差15)。
- 全局发育商的最小临床重要差值为5分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为探索性二次分析。
- 作者指出需进一步随机研究以对氢化可的松在极早产儿中的神经发育安全性提供确切评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dexamethasone to prevent bronchopulmonary dysplasia in very preterm neonates was associated with adverse neurodevelopmental events. Early low-dose hydrocortisone treatment has been reported to improve survival without bronchopulmonary dysplasia but its safety with regard to neurodevelopment remains to be assessed. OBJECTIVE: To assess whether early hydrocortisone therapy in extremely preterm infants is associated with neurodevelopmental impairment at 2 years of age. DESIGN, SETTING, AND PARTICIPANTS: An exploratory secondary analysis of the PREMILOC (Early Low-Dose Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia in Extremely Preterm Infants) randomized clinical trial conducted between 2008 and 2014 in 21 French neonatal intensive care units. Randomization was stratified by gestational age groups. Neurodevelopmental assessments were completed from 2010 to 2016. INTERVENTIONS: After birth, patients were randomly assigned to receive placebo or hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days). MAIN OUTCOMES AND MEASURES: The prespecified exploratory secondary outcome of neurodevelopmental impairment was based on a standardized neurological examination and the revised Brunet-Lézine scale (global developmental quotient score and subscores; mean norm, 100 [SD, 15]). The minimal clinically important difference on the global developmental quotient was 5 points. RESULTS: Of 1072 neonates screened, 523 were assigned to hydrocortisone (n = 256) or placebo (n = 267) and 406 survived to 2 years of age. A total of 379 patients (93%; 46% female) were evaluated (194 in the hydrocortisone group and 185 in the placebo group) at a median corrected age of 22 months (interquartile range, 21-23 months). The distribution of patients without neurodevelopmental impairment (73% in the hydrocortisone group vs 70% in the placebo group), with mild neurodevelopmental impairment (20% in the hydrocortisone group vs 18% in the placebo group), or with moderate to severe neurodevelopmental impairment (7% in the hydrocortisone group vs 11% in the placebo group) was not statistically significantly different between groups (P = .33). The mean global developmental quotient score was not statistically significantly different between groups (91.7 in the hydrocortisone group vs 91.4 in the placebo group; between-group difference, 0.3 [95% CI, -2.7 to 3.4]; P = .83). The incidence of cerebral palsy or other major neurological impairments was not significantly different between groups. CONCLUSIONS AND RELEVANCE: In this exploratory analysis of secondary outcomes of a randomized clinical trial of extremely preterm infants, early low-dose hydrocortisone was not associated with a statistically significant difference in neurodevelopment at 2 years of age. Further randomized studies are needed to provide definitive assessment of the neurodevelopmental safety of hydrocortisone in extremely preterm infants. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00623740.
引用
- Baud O, Trousson C, Biran V, et al. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. JAMA. 2017. PMID: 28384828. doi:10.1001/jama.2017.2692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。